Pacific Edge's revenue climbs, US future still uncertain

Pacific Edge's revenue climbs, US future still uncertain
Very strong revenue growth, but profit still some distance away (Image: Pacific Edge)
Ella Somers
A boom in Pacific Edge’s Cxbladder test sales boosted the firm’s operating revenue soar by 71%, with a helping hand from favourable exchange rates.Chief executive Peter Meintjes said the 2023 financial year had been a year of “enormous change and achievement” for the cancer diagnostic company.“Pacific Edge is geared for growth,” he told the NZX.Operating revenue for the twelve months to March 31 rose $19.6 million, up from $11.4m in the previous year while total revenue jumped 88% to $26.1m.The revenue climb...

More Markets

NZ sharemarket flat amid Tourism Holdings trading halt
Markets Market close

NZ sharemarket flat amid Tourism Holdings trading halt

The S&P/NZX 50 Index closed at 11,874.04, up 6.46 points or 0.05%.

THL halts trading on 'materially lower' earnings expectations
Markets

THL halts trading on 'materially lower' earnings expectations

In February THL's net profit guidance for FY2024 was $75m.

BNZ's 1H profit and margins ease
Markets

BNZ's 1H profit and margins ease

Net profit was down 5.3% on the previous year's first half. 

NZ sharemarket falls due to global inflation fears
Markets Market close

NZ sharemarket falls due to global inflation fears

The S&P/NZX 50 Index closed at 11,867.58, down 89.92 points or 0.75%.

Graham Skellern 01 May 2024